Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors 12

• Material Type: 博士論文
• ISSN: 1932-6203
• Title: Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors
• Volume: 8 12
• Author/Editor: Harada, Takeshi; Ozaki, Shuji; Oda, Asuka; Tsuji, Daisuke; Ikegame, Akishige; Iwasa, Masami; Udaka, Kengo; Fujii, Shiro; Nakamura, Shingen; Miki, Hirokazu; Kagawa, Kumiko; Kuroda, Yoshiaki; Kawai, Shigeto; Itoh, Kohji; Yamada-Okabe, Hisafumi; Matsumoto, Toshio; Abe, Masahiro
• Author Heading: Harada, Takeshi; Ozaki, Shuji; Oda, Asuka; Tsuji, Daisuke; Ikegame, Akishige; Iwasa, Masami; Udaka, Kengo; Fujii, Shiro; Nakamura, Shingen; Miki, Hirokazu; Kagawa, Kumiko; Kuroda, Yoshiaki; Kawai, Shigeto; Itoh, Kohji; Yamada-Okabe, Hisafumi; Matsumoto, Toshio; Abe, Masahiro
• Publication, Distribution, etc.: PLOS
• Publication Date: 2013-12-26
• Publication Date (W3CDTF): 2013-12-26
• Alternative Title: 低フコース化抗HM1.24抗体とレナリドミドの併用は骨髄腫細胞および骨髄腫細胞幹細胞に著明なADCC活性を示す; Combination of Defucosylated AHM plus Lenalidomide
• Periodical title: PLOS ONE
• Degree grantor/type: 徳島大学
• Date Granted: 2014-03-24
• Date Granted (W3CDTF): 2014-03-24
• Dissertation Number: 甲第2668号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第2668号
• Text Language Code: eng
• Subject Heading: Multiple myeloma; HM1.24; Lenalidomide; ADCC
• Target Audience: 一般
• Note (General): The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cells. In this study, we evaluated ADCC by YB-AHM and Len in combination against MM cells and their progenitors. YB-AHM was able to selectively kill via ADCC MM cells in bone marrow samples from patients with MM with low effector/target ratios, which was further enhanced by treatment with Len. Interestingly, Len also up-regulated HM1.24 expression on MM cells in an effector-dependent manner. HM1.24 was found to be highly expressed in a drug-resistant clonogenic ‘‘side population’’ in MM cells; and this combinatory treatment successfully reduced SP fractions in RPMI 8226 and KMS-11 cells in the presence of effector cells, and suppressed a clonogenic potential of MM cells in colony-forming assays. Collectively, the present study suggests that YB-AHM and Len in combination may become an effective therapeutic strategy in MM, warranting further study to target drug-resistant MM clonogenic cells.
• DOI: info:doi/10.1371/journal.pone.0083905; https://doi.org/info:doi/10.1371/journal.pone.0083905
• Persistent ID (NDL): info:ndljp/pid/9984223; https://dl.ndl.go.jp/pid/9984223
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2016-06-03T01:05:16+09:00
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://repo.lib.tokushima-u.ac.jp/106068
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp